Thursday, April 30, 2026

The FDA and CMS jointly announced the RAPID Coverage Pathway, a new program designed to accelerate Medicare coverage for FDA-designated breakthrough medical devices. The goal is to reduce the lag between FDA approval and CMS national coverage determinations, which historically has taken years. The program involves concurrent review and more predictable coverage outcomes. For practices that adopt qualifying breakthrough technologies, this could mean faster payer adoption and reduced uncertainty in patient coverage. The agencies will release operational details and a list of initial qualifying devices later this year. Monitor CMS and FDA announcements in Q3 2026 for the initial device list and specific coverage parameters, which will dictate which new technologies your practice can plan to adopt with confidence in reimbursement.

UnitedHealthcare, Aetna, and Cigna, as part of an industry-wide commitment led by AHIP and the BCBS Association, report progress toward standardizing electronic prior authorization. The insurers claim the initiative, which began in early 2025, is reducing manual paperwork and speeding decisions. According to the report, health plans have achieved an 11% reduction in prior authorization requirements overall since the start of the program. While the promise is faster, automated decisions, the onus remains on practices to ensure their EHRs and practice management systems are updated to interface with payer-specific portals and APIs. This is a signal of continued pressure from federal rules mandating electronic prior auth, but concrete workflow changes for practices will depend on their specific payer mix and technology integrations.

Analyst commentary from KeyBanc Capital Markets suggests CMS is likely to add dedicated CPT codes for the Inspire V upper airway stimulation implant for sleep apnea in the upcoming 2027 Physician Fee Schedule. The firm's note, which moved the manufacturer's stock, indicates this would be a positive reimbursement update for otolaryngology and sleep medicine practices offering the therapy. Currently, the procedure may be billed with existing neuromodulation or implantation codes, but a specific code could lead to more consistent payment rates and reduced adjudication confusion. The 2027 PFS proposed rule, expected in July 2026, will be the first official source to confirm or deny this change. ENT and sleep practices should monitor the July 2026 CMS proposed rule for specific code proposals related to hypoglossal nerve stimulation.

Federal lawmakers introduced the Streamlining Medicare Advantage Prior Authorization Act. The bill targets Medicare Advantage (MA) plans, requiring them to provide real-time decisions on routine prior authorization requests and to honor approvals for a full plan year. The legislation cites MA plans' higher utilization of prior authorization compared to traditional Medicare. This bill enters a Congress with prior authorization reform as a rare point of bipartisan agreement. The outcome could force MA plan behavior changes. Track the bill's progress through committee for potential changes to payer workflows.